Supplemental materials for utility of multimodality approach including systemic FGF23 venous sampling in localizing phosphaturic mesenchymal tumors
Hajime Katô(University of Tokyo Hospital), Nobuaki Ito(University of Tokyo Hospital), Makoto Arai(Tohoku University), Masaki Katsura(University of Tokyo Hospital), Tetsuo Ushiku(The University of Tokyo), Masaomi Nangaku(The University of Tokyo), Hiroshi Kobayashi(The University of Tokyo), Yuji Nakamoto(Kyoto University Hospital), Yuichi Takashi(Fukuoka University), Yoshitomo Hoshino(University of Tokyo Hospital), Yuka Kinoshita(University of Tokyo Hospital), Naoko Hidaka(University of Tokyo Hospital), Noriko Makita(University of Occupational and Environmental Health Japan), Minae Koga(University of Tokyo Hospital), Naohiro Makise(Chiba Cancer Center), Kazuto Hoshi(University of Tokyo Hospital), Seiji Fukumoto(Tokushima Hospital)
Cited by 0
Related Papers
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
|The Lancet|2017|923
Chemical Landscape for Tissue Clearing Based on Hydrophilic Reagents
|Cell Reports|2018|369
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period
|Calcified Tissue International|2019|160
Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference
|Kidney International|2017|149
X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment
|Endocrine Reviews|2018|148